Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Adenosine Triphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 8/20 | 0.78 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.78 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.78 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.78 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.78 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.78 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.78 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.78 |
| ▸ | LDHA | P00338 | 1/20 | 0.78 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.78 |
| ▸ | FBP1 | P09467 | 1/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.78 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.78 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL30185881 | 0.98 | P2RY1 (0.78) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Triphosphate SCHEMBL1496211 | 0.98 | P2RY1 (0.78) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Triphosphate SCHEMBL31091233 | 0.97 | P2RY1 (0.77) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Triphosphate SCHEMBL29653413 | 0.97 | P2RY1 (0.77) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Triphosphate SCHEMBL8852600 | 0.97 | P2RY1 (0.77) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL4406439 | 0.96 | P2RY1 (0.80) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL29352453 | 0.96 | P2RY1 (0.80) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL30936537 | 0.95 | P2RY1 (0.79) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Triphosphate SCHEMBL3040412 | 0.95 | P2RY1 (0.78) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Triphosphate SCHEMBL3040417 | 0.95 | P2RY1 (0.78) | P2RY1P2RY2P2RX1P2RX3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166533-A1 | SYNERGISTIC COMPOSITIONS AND METHODS FOR POTENTIATING ANTI-OXIDATIVE ACTIVITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZAT (IL) | 2016-06-16 | — | — | US | disclosed |
| US-9060959-B2 | Synergistic compositions and method for potentiating anti-oxidative activity | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2015-06-23 | — | — | US | disclosed |
| US-20130017263-A1 | GASTRIC ACID SECRETION INHIBITING COMPOSITION | OREXO AB (SE) | 2013-01-17 | — | — | US | disclosed |
| US-20120121664-A1 | Gastric Acid Secretion Inhibiting Composition | OREXO AB (SE) | 2012-05-17 | — | — | US | disclosed |
| EP-2258341-A2 | Gastric acid secretion inhibiting composition | Orexo AB (SE) | 2010-12-08 | — | — | EP | disclosed |
| US-7785626-B2 | Gastric acid secretion inhibiting composition | OREXO AB (SE) | 2010-08-31 | — | — | US | disclosed |
| US-7771747-B2 | Gastric acid secretion inhibiting composition | OREXO AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20100151013-A1 | Gastric acid secretion inhibiting composition | OREXO AB | 2010-06-17 | — | — | US | disclosed |
| EP-1713476-B1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLES | LYKA LABS LTD (IN) | 2010-05-05 | — | — | EP | disclosed |
| EP-1587805-B1 | PHARMACEUTICAL PROCESS AND COMPOUNDS PREPARED THEREBY | CIPLA LTD (IN) | 2009-04-22 | — | — | EP | disclosed |
| WO-2006000567-A2 | USE OF GLP-1 RECEPTOR AGONISTS AND / OR DPP-IV INHIBITORS IN COMBINATION WITH PROTON PUMP INHIBITORS AND PPAR AGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF DIABETES TYPE I I AND IMPAIRED PANCREATIC BETA-CELL FUNCTION | NOVO NORDISK A/S (DK) | 2006-01-05 | — | — | WO | disclosed |
| EP-1596821-A2 | SYNERGISTIC COMPOSITIONS AND METHODS FOR POTENTIATING ANTI-OXIDATIVE ACTIVITY | THE STATE OF ISRAEL-MINISTRY OF AGRICULTURE (IL) | 2005-11-23 | — | — | EP | disclosed |
| EP-1594499-A1 | DOSAGE FORMS CONTAINING A PROTON PUMP INHIBITOR, A NSAID, AND A BUFFER | TAP Pharmaceutical Products, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1587805-A1 | PAHARMACEUTICAL PROCESS AND COMPOUNDS PREPARED THEREBY | Cipla Ltd. (IN) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005065682-A2 | RABEPRAZOLE CONTAINING FORMULATION | LYKA LABS LIMITED (IN) | 2005-07-21 | — | — | WO | disclosed |
| WO-2004064719-A2 | SYNERGISTIC COMPOSITIONS AND METHODS FOR POTENTIATING ANTI-OXIDATIVE ACTIVITY | STATE OF ISRAEL, MINISTRY OF AGRICULTURE (IL) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004063188-A1 | PAHARMACEUTICAL PROCESS AND COMPOUNDS PREPARED THEREBY | CIPLA LIMITED (IN) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004060372-A1 | DOSAGE FORMS CONTAINING A PROTON PUMP INHIBITOR, A NSAID, AND A BUFFER | TAP PHARMACEUTICAL PRODUCTS INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040131676-A1 | Dosage forms containing a PPI, NSAID, and buffer | TAP PHARMACEUTICAL PRODUCTS INC. | 2004-07-08 | — | — | US | disclosed |
| US-20040121004-A1 | Dosage forms containing a PPI, NSAID, and buffer | TAP PHARMACEUTICAL PRODUCTS INC. | 2004-06-24 | — | — | US | disclosed |